Vaccines 2024

2nd International Conference on

Virology and Vaccines

May 17-18, 2024

Theme: “Exploring next-generation vaccines: research, diagnostics and treatment that save lives”

Days
Hours
Minutes
Seconds

Vaccines 2024 | WEBINAR

New Updates

First Round of Abstract Submission is Open Now.....
Why to choose Sciencezo Planet

Webinar & Conferences

WHAT WE DO?

Sciencezo Planet Conferences organizes conferences, meetings, seminars and workshops with the ingenious and peerless speakers throughout the world providing you and your organization with a broad range of networking opportunities to capitalize on the knowledge of practicing members across several disciplines to understand the impact of science in modern world.

WHO WE ARE?

Sciencezo Planet Conferences provides an opportunity for leading academicians, scientists, researchers, doctors, medical practitioners, nurses and various industry professionals from around the world to network and have scientific discussion on the latest advancements and interlinked domains in science, medicine and health.

WHAT IS OUR VISION?

Sciencezo Planet is proficient in organizing conferences, meetings, seminars and workshops with the ingenious and peerless speakers throughout the world providing you and your organization with a broad range of networking opportunities to globalize your research and create your own identity in the scientific community.

WHAT IS OUR MISSION?

Our main mission is to make our conferences highly successful with high quality interactive technical sessions with recent research findings of the latest and futuristic trends exposed as we focus on providing workshops and symposiums organized through well-established industrial and academic tie-ups with various professional bodies.

Renowned

Speakers

Srđan Stankov

Pasteur Institute Novi Sad
Serbia
Pasteur Institute Novi Sad, Serbia

Mic McGoldrick

Global CMC Policy at Merck
USA
Global CMC Policy at Merck, USA

Zheng Zhu

Fujian Medical University
China
Fujian Medical University, China

Michael Kishko

Sanofi Pasteur
USA
Sanofi Pasteur, USA

Yongjun Sui

National Institutes of Health
USA
Sanofi Pasteur, USA

Domenico Merante

Global Clinical Development
Switzerland
Global Clinical Development, Switzerland

Zachary Hartman

Duke University
USA
Duke University, USA

Catherine N. Kibirige

Imperial College London
UK
Imperial College London, UK

Albert J. Auguste

Virginia Polytechnic Institute and State University
USA
Virginia Polytechnic Institute and State University, USA

Scientific

Sessions

The COVID-19 pandemic has led to an unprecedented effort to develop vaccines to protect against the disease caused by the SARS-CoV-2 virus. Scientists around the world have worked tirelessly to develop and test various vaccine candidates, with several vaccines receiving emergency use authorization or approval from regulatory agencies.

Vaccine immunology is the study of how vaccines stimulate the immune system to produce a protective response against infectious diseases. Vaccines work by introducing a small amount of a pathogen or its components into the body, which triggers an immune response.

Immunotherapy, on the other hand, is a type of medical treatment that uses the immune system to fight diseases such as cancer, autoimmune disorders, and infectious diseases.

Emerging and re-emerging infectious diseases are illnesses caused by pathogens that have recently appeared or are becoming more prevalent. These diseases can pose significant public health challenges due to their ability to spread rapidly, often with no specific treatment or vaccine available.

Examples include the Ebola virus, Zika virus, and SARS-CoV-2, the virus responsible for COVID-19.

Cancer vaccines are designed to stimulate the immune system to recognize and attack cancer cells. These vaccines can be made from cancer cells or specific cancer antigens, which are the proteins on the surface of cancer cells that the immune system recognizes as foreign. When the vaccine is given, it stimulates the immune system to produce antibodies and T cells that can recognize and destroy cancer cells.

Immunotherapy is a type of cancer treatment that enhances the ability of the immune system to identify and kill cancer cells.

Immuno-genetics is the study of the genetic basis of the immune system and how genetic variations can impact immune function and disease susceptibility. The immune system is a complex network of cells and molecules that work together to protect the body from infections, cancer, and other threats.

Immune tolerance, on the other hand, is the ability of the immune system to distinguish between self and non-self antigens. This is critical for preventing the immune system from attacking the body’s own tissues, leading to autoimmune diseases

Immune disorders are a group of conditions where the immune system either overreacts or underreacts to foreign antigens or the body’s own tissues. These disorders include autoimmune diseases, immunodeficiencies, and hypersensitivities.

Allergies occur when the immune system overreacts to harmless substances, such as pollen, pet dander, or certain foods, leading to allergic reactions. Asthma is a chronic inflammatory disease of the airways that can be triggered by allergens, air pollution, or respiratory infections, leading to symptoms such as wheezing, coughing, and shortness of breath.

Epidemiology and parasitology are two branches of biology that study the spread and control of infectious diseases.

The fields of epidemiology and parasitology are closely related, as many infectious diseases are caused by parasitic organisms. Epidemiologists and parasitologists work together to understand the transmission and distribution of parasitic diseases, identify risk factors associated with infection, and develop strategies for their prevention and control. This can involve a range of interventions, including improved sanitation, vector control, and drug treatments.

Influenza is a seasonal disease, with outbreaks occurring mainly in the winter months. Vaccines are available to prevent the flu and are recommended for individuals at high risk of complications, such as young children, elderly individuals, and people with underlying medical conditions.

Respiratory diseases are a group of conditions that affect the lungs and other parts of the respiratory system. Common respiratory diseases include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and tuberculosis. These diseases can cause a range of symptoms, including coughing, wheezing, shortness of breath, and chest pain.

Protein-based vaccines are a type of vaccine that uses proteins or protein fragments from a pathogen to stimulate an immune response in the body. It work by presenting the immune system with a specific protein or protein fragment from the pathogen.

Protein-based vaccines are a promising approach to preventing and treating infectious diseases and other conditions. Ongoing research and development in this field may lead to the development of new and more effective vaccines for a range of health threats.

Veterinary vaccines are used to prevent diseases in livestock, pets, and wildlife, they are made from either killed or modified forms of the pathogen, or from proteins or peptides that mimic the pathogen.

HIV/AIDS vaccines are vaccines that are designed to prevent infection with HIV, the virus that causes AIDS. These vaccines are still in development, and none are currently available for widespread use.

Hepatitis vaccines are vaccines that are designed to protect against hepatitis, a viral infection that affects the liver. There are several types of hepatitis, including hepatitis A, B, C, D, and E.

Antibody engineering involves modifying the structure of antibodies to improve their specificity, stability, and efficacy. This can be done using techniques such as genetic engineering, phage display, and hybridoma technology.

Antibody engineering and therapeutics are a rapidly advancing field with the potential to revolutionize the treatment of many diseases. Ongoing research and development in this area may lead to the development of new and more effective treatments for a range of health conditions.

Vaccines are an important tool in the prevention and control of infectious diseases. To ensure their safety and efficacy, vaccines undergo rigorous testing and evaluation through clinical trials.

Throughout the clinical trial process, vaccine safety is closely monitored. Adverse reactions are carefully documented and reported to regulatory agencies. If safety concerns arise, the trial may be halted or modified to address the issue, the safety and efficacy of vaccines are critical considerations in their development and use. Through rigorous clinical testing and ongoing monitoring, vaccines can be developed and used with confidence to protect against a range of infectious diseases.

Both DNA and RNA vaccines have several advantages over traditional vaccines. They can be produced more quickly and at a lower cost than traditional vaccines, and they do not require the use of live or inactivated pathogens. Additionally, they can be easily modified to target new strains of a pathogen or to address emerging infectious diseases.

Both DNA and RNA vaccines have shown promise in preclinical and clinical studies, and are being developed for a range of infectious diseases, including COVID-19, influenza, and Zika virus.

Before a vaccine candidate can advance to clinical trials, it must undergo extensive pre-clinical validation to assess its safety, immunogenicity, and efficacy. This process involves several stages of testing in the laboratory and in animal models, once pre-clinical validation is complete and the vaccine candidate is deemed safe and effective in animal models, it can move on to clinical trials.

The pre-clinical validation and clinical trial process is essential for ensuring the safety and efficacy of vaccines, and for bringing new vaccines to market to prevent and control infectious diseases.

These next-generation vaccine delivery technologies have the potential to improve vaccine effectiveness, reduce the need for needles, and increase accessibility to vaccines, particularly in remote or resource-limited areas. Ongoing research and development in this area will continue to advance vaccine delivery technology and improve the prevention and control of infectious diseases.

Several novel approaches and new trends in vaccines development that are being explored to improve the effectiveness, safety, and accessibility of vaccines. Some of these approaches include: mRNA vaccines | Virus-like particle (VLP) vaccines | Live-attenuated vaccines | Synthetic peptide vaccines | Multi-epitope vaccines | Personalized cancer vaccines | Plant-based vaccines.

These novel approaches and new trends in vaccines development have the potential to revolutionize the field of vaccinology and improve the prevention and treatment of infectious diseases, cancer, and other illnesses. Ongoing research and development will continue to advance these approaches and bring new vaccines to market.

Vaccination advancement and immunization refer to the progress and improvements made in the development, delivery, and utilization of vaccines to protect individuals and populations against infectious diseases. The advancement of vaccines and immunization has been one of the most successful public health interventions in history, preventing millions of deaths and illnesses worldwide.

Over the past few decades, there have been significant advancements in vaccine development and production, including the use of new technologies such as recombinant DNA, cell culture, and bioinformatics. This has led to the development of new and improved vaccines for a range of diseases, including human papillomavirus (HPV), rotavirus, pneumococcal disease, and meningococcal disease.

Vaccine policy and advocacy refer to the actions taken by governments, public health organizations, and other stakeholders to promote the development, distribution, and use of vaccines to prevent and control infectious diseases. Some examples of vaccine policy and advocacy initiatives include: Vaccine Mandates | Vaccine Financing | Public Health Messaging | Vaccine Research | Global Vaccine Access | Vaccine Injury Compensation | Vaccine Supply Chain Management.

Vaccine policy and advocacy are important for ensuring that vaccines are developed, distributed, and used effectively to prevent and control infectious diseases. By promoting vaccination, policymakers and advocates can help to reduce the burden of vaccine-preventable diseases and improve public health outcomes.

Vaccines for pregnant women and neonates are an important public health strategy for protecting vulnerable populations from infectious diseases. Vaccines given during pregnancy can protect both the mother and her developing fetus, while vaccines given to neonates can provide early protection against infections. Healthcare providers can provide guidance on the appropriate vaccination schedule for pregnant women and neonates based on the latest recommendations from public health authorities.

Ebola and Zika are both viral infections that can cause serious illness in humans. However, they are caused by different viruses and have distinct characteristics and modes of transmission.

Both Ebola and Zika virus infections are of public health concern and require immediate attention and response from the global health community. Prevention measures such as using insect repellent to prevent mosquito bites and avoiding direct contact with bodily fluids of infected individuals or animals can help prevent transmission. Early detection and treatment are also crucial to improving outcomes and reducing the spread of these diseases.

Conference

Schedule

DAY-1

May 17, 2024
  • 09:00-09:30 Opening Ceremony and Introduction
  • 09:30-10:30 Keynote Session I
  • 10:30-11:00 Refreshment Break
  • 11:00-12:30 Keynote Session II
  • 12:30-13:30 Lunch
  • 13:30-15:00 Break Out Session I
  • 15:00-15:30 Refreshment Break
  • 15:30-18:00 Break Out Session II
Webnair

DAY-2

May 18, 2024
  • 09:00-09:30 Opening Ceremony and Introduction
  • 09:30-10:30 Keynote Session I
  • 10:30-11:00 Refreshment Break
  • 11:00-12:30 Keynote Session II
  • 12:30-13:30 Lunch
  • 13:30-15:00 Break Out Session I
  • 15:00-15:30 Refreshment Break
  • 15:30-18:00 Break Out Session II
Webnair

Important

Dates

Abstract Submission

January 30, 2024

January 30, 2024

First round submission deadline

Early Bird Registration(Open)

January 30, 2024

January 30, 2024

Early bird registration deadline (Open)

Get your (Early Bird)

Registration

ACADEMIC
REGISTRATION

$

99

BUSINESS
REGISTRATION

$

149

STUDENT
REGISTRATION

$

49

Media

Partners